Skip to main content
Fig. 8 | Journal of Hematology & Oncology

Fig. 8

From: The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1

Fig. 8

Flow cytometry assays to analyze the tumor immune microenvironment in EMT-6 tumors. Representative images of a tumor-infiltrating lymphocytes, b T cells, c granzyme B+ T cells, d CD107a+ T cells, e CD8+ T cells, f dendritic cells (DCs), g macrophages. The relative quantitative analysis was performed by the ratio of tumor-infiltrating immune cells to total alive cells in the prepared cell suspension. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 denote the significant difference relative to YM101 treatment. α-TGF-β: anti-TGF-β, α-PD-L1: anti-PD-L1

Back to article page